Matthew Burkhardt

Matthew has over 15 years’ experience in target and asset discovery across academic, startup, and Pharma organizations. He started in traumatic brain injury with the Neurosurgery Department at the University of Pennsylvania, moved to industry with Merck for in vivo Alzheimer’s Disease small molecule drug discovery, and then moved to iPierian, one of the first companies to use the induced pluripotent stem cell (iPSC) platform. Matthew has held further positions at the Allen Institute for Brain Science and Novartis. He is the current Director at B+labs in Philadelphia, PA, an incubation site for early- and growth-stage clinically oriented therapeutic companies. Matthew also serves as SAB Chair for the Schinzel-Giedion Syndrome Foundation, a UK-based non-profit patient advocacy organization supporting research and discovery efforts for children with SGS.